Financial Performance - The company's revenue for Q1 2023 was ¥331,932,094.69, representing a 46.54% increase compared to ¥226,514,694.52 in the same period last year[5] - Net profit attributable to shareholders was ¥77,711,739.74, up 27.79% from ¥60,813,979.13 year-on-year[5] - The company achieved a basic earnings per share of ¥0.2865, reflecting a 29.17% increase from ¥0.2218 in the same period last year[5] - Total operating revenue for Q1 2023 reached ¥331,932,094.69, a significant increase of 46.6% compared to ¥226,514,694.52 in the same period last year[23] - Operating profit for Q1 2023 was ¥85,536,589.74, representing a 27.1% increase from ¥67,273,409.04 in the previous year[23] - The total comprehensive income for the first quarter was approximately ¥77.11 million, compared to ¥60.54 million in the same period last year[24] Cash Flow - The net cash flow from operating activities improved significantly, reaching -¥5,927,387.04, a 79.86% increase from -¥29,426,149.07 in the previous year[5] - Cash flow from operating activities showed a net outflow of approximately ¥5.93 million, an improvement from a net outflow of ¥29.43 million in Q1 2022[26] - The company reported cash inflows from investment activities of approximately ¥193.31 million, a decrease from ¥572.60 million in the same quarter last year[26] - The net cash flow from financing activities was negative at approximately ¥3.03 million, compared to a negative cash flow of ¥49.94 million in Q1 2022[27] - The company experienced a foreign exchange loss impacting cash and cash equivalents of approximately ¥2.10 million during the quarter[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,995,901,600.82, a 2.41% increase from ¥2,925,260,842.41 at the end of the previous year[5] - Current assets totaled ¥1,855,503,424.29 at the end of the period, an increase from ¥1,828,452,182.29 at the beginning of the year[20] - The company’s total liabilities decreased to ¥991,927,746.93 from ¥1,005,435,860.00, indicating a reduction of 1.3%[21] - Cash and cash equivalents at the end of the period were ¥814,664,022.59, down from ¥838,136,028.79 at the beginning of the year, a decrease of 2.8%[20] - Inventory increased to ¥429,391,781.06 from ¥375,902,952.82, marking a rise of 14.2%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,048, with the largest shareholder holding 28.08% of the shares[13] - In Q1 2023, the company reported a total of 33,123,600 shares held by Guangdong Hengjian International Investment Co., accounting for 12.04% of total shares[14] - Shareholder Song Jie holds 18,633,103 shares, representing 6.77% of total shares, while Song Yong holds 11,091,800 shares, or 4.03%[14] - The company’s major shareholders include China Construction Bank with 13,500,000 shares (4.91%) and other investment funds holding significant stakes[14] - As of March 31, 2023, the total number of restricted shares held by Song Jie decreased by 5,626,650 shares, leaving 17,009,070 shares[17] Expenses and Investments - The company reported a significant increase in sales expenses, which rose by 106.97% to ¥5,487,000, primarily due to increased personnel costs and market expansion efforts[10] - The investment income increased by 27.77% to ¥831,000, attributed to higher returns from investments in Ningbo Ruiyuan[10] - The company invested ¥22,230,348.74 in R&D during Q1 2023, compared to ¥20,677,466.87 in the same period last year, showing an increase of 7.5%[23] Other Financial Metrics - The company recorded a decrease in cash flow from investing activities, which fell by 110.92% to -¥14,134,470.00, mainly due to a reduction in the redemption of financial products[11] - The company reported a net profit attributable to shareholders of ¥1,282,855,282.37, up from ¥1,205,049,756.63 at the beginning of the year, reflecting a growth of 6.4%[21] - Total operating costs for Q1 2023 were ¥261,998,562.12, up 54.5% from ¥169,474,938.59 in Q1 2022[23] - The cumulative percentage of shares held by major shareholder Song Jie and her concerted parties decreased by 5.00% during the reporting period[18] - The company announced plans to adjust the repurchase price of its 2021 and 2022 restricted stock incentive plans, pending approval at the 2022 annual shareholders' meeting[18] - The company’s financial statements for Q1 2023 are compiled as of March 31, 2023, indicating ongoing financial assessments[19]

（二）中国基金报-机会宝网上路演中心 1、时间：2023 年 4 月 21 日（星期五）15：00 至 17：00； 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-027 迪瑞医疗科技股份有限公司 关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）《2022 年年度报告》及 其摘要于 2023 年 4 月 18 日在中国证监会指定的创业板信息披露网站上披露。为 便于投资者进一步了解公司的生产经营等情况，公司拟定于 2023 年 4月 21 日（星 期五）15：00 至 17：00 采取网络远程的方式举办 2022 年年度报告网上业绩说 明会。 投资者可通过以下方式参与，具体方式如下： （一）全景•路演天下 1、时间：2023 年 4 月 21 日（星期五）15：00 至 17：00； 2、参与方式：投资者可登陆"全景•路演天下（https://ir.p5w.net）参与互动 交流。 2023 年 4 月 17 日 2、参 与 方 式 ： 投 资 者 ...

Group 1: R&D and Product Development - The company has accumulated significant core technologies over 20 years, including automatic light tracking technology for urine analyzers and interference algorithms based on fuzzy technology [2] - Current R&D products include the CS-9200 fully automatic biochemical analysis line and the FUS-3000 fully automatic urine analysis workstation [2] Group 2: Distributor Management - Since the end of 2012, the company has actively adjusted its distributor management policy, focusing on selecting and supporting high-quality distributors [3] - The company has ceased direct supply to some distributors with low transaction volumes, transitioning them to secondary distributors [3] Group 3: Subsidiary Establishment - The company has established a wholly-owned subsidiary in Shanghai with a registered capital of RMB 20 million, focusing on the distribution of related medical device products [3] Group 4: Product Selection Recognition - In May 2014, the National Health and Family Planning Commission initiated the selection of excellent domestic medical equipment, evaluating 218 products and selecting 96 from 27 companies [4] - The company's products, including CS-1600 and CS-T300, were included in the list of selected excellent domestic medical equipment [4]

Group 1: Company Overview and Investor Relations - The company is Changchun Dirui Medical Technology Co., Ltd., with stock code 300396 and abbreviation Dirui Medical [1] - The investor relations activity was conducted on August 21, 2015, in the company's conference room [3] - Participants included representatives from various funds, such as Bosera Fund and Guotai Junan [2][3] Group 2: Product Development and Sales Strategy - The company is currently registering the CM-240 fully automated chemiluminescence immunoassay analyzer and has over 30 chemiluminescence immunoassay reagents in small-scale R&D [3][4] - Sales for chemiluminescence products will utilize a distributor model, with a focus on building a sales team through internal selection and external recruitment [3][4] - The company plans to implement market promotion strategies based on product performance and market conditions [4] Group 3: Financial Performance and R&D Investment - In the first half of 2015, the company's R&D expenses increased significantly due to new product development and registration costs [5][6] - The R&D team has been developed over nearly 20 years, with a focus on multi-disciplinary talent to support product innovation [6] - The company reported a 33% increase in reagent product revenue in the first half of 2015, with urine-related reagent products also experiencing around 30% growth [7] Group 4: Future Directions and Market Expansion - The company aims to cover approximately 50% of hospital testing items and plans to expand into areas such as immunology, biochemistry, hematology, microbiology, POCT, and molecular diagnostics [6][7] - Future growth may involve exploring autonomous R&D or external acquisitions to enhance the technology and product line [7] - The company is actively considering stock incentive plans and employee shareholding schemes [7]

Group 1: Product Development and Sales Strategy - The company has obtained the medical device registration certificate for the fully automated chemiluminescence analyzer CM-240 from the Jilin Provincial Food and Drug Administration [2] - The sales strategy has been adjusted to increase bundled sales of instruments and reagents, leading to a 20% growth in reagent sales [2] - The company is focusing on enhancing its sales network and establishing overseas offices for product registration and certification [2] Group 2: Financial Performance - Revenue from reagent products reached 91 million yuan, a year-on-year increase of 20% [3] - Revenue from test paper products was 54 million yuan, with a year-on-year growth of 5% [3] - Instrument product revenue amounted to 196 million yuan, with blood cell reagent revenue exceeding 10 million yuan, reflecting a growth of over 40% [3] Group 3: Integration and Collaboration - The company has completed the business registration change for Ningbo Ruiyuan and is exploring cooperative strategies while maintaining competitive dynamics [2] - The collaboration will involve leveraging the company's instrument products to boost the sales of Ruiyuan's reagent products and vice versa [2]

证券代码： 300396 证券简称： 迪瑞医疗 长春迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | 工银瑞信基金 谭冬寒 | | | | 广发资产 毛丁丁 | | | 参与单位名称及 | 上投摩根基金 张飞、征茂平 | | | | | | | 人员姓名 | 望正资产 王琦 | | | | 西南证券 朱国广、周平、赵佳 | | | | 银华基金 王浩 | | | 时间 | 2016 年 2 月 18 | 日下午 | | 地点 | 迪瑞医疗公司会议室 | | | 上市公司接待 | 董事会 ...

Financial Performance - In the first half of the year, the company achieved operating revenue of 335 million CNY, a year-on-year increase of 48.08% [3] - Operating profit reached 78.57 million CNY, up 78.43% compared to the same period last year [3] - Net profit attributable to shareholders was 62.45 million CNY, reflecting a growth of 30.03% year-on-year [3] - The company's subsidiary, Ningbo Ruiyuan, reported operating revenue of 88.34 million CNY and net profit of 31.60 million CNY [3] Revenue Breakdown - Instrument revenue accounted for 135 million CNY, while test paper products generated 36 million CNY and reagent revenue was 164 million CNY [3] - Domestic revenue was 265 million CNY, showing a growth of 55.29%, while international revenue approached 70 million CNY, increasing by 25.71% [3] Product Development - As of June 2016, the company had 51 chemical luminescence reagent products in the approval stage [4] - The CM-240 fully automated chemical luminescence analyzer has received registration certification from the Jilin Provincial Food and Drug Administration [4] Strategic Direction - The company aims to enhance governance structure, improve management efficiency, and increase profitability to maximize investor value [3] - Future plans include expanding into new business areas through acquisitions and mergers [3] Sales Strategy - The sales team for chemical luminescence products is being developed through a combination of internal selection and external recruitment [4] - The sales approach will continue to utilize a distributor model, with targeted marketing strategies based on market conditions and product performance [4] Vision and Market Position - The company aspires to become a global service provider for laboratory solutions, currently covering about 50% of hospital testing projects [4] - Plans to enter fields such as immunology, biochemistry, hematology, microbiology, POCT, and molecular diagnostics are underway to achieve comprehensive development in the IVD sector [4]